https://orcid.org/0000-0002-5503-5337
Key Points
Development of a novel AAV-compatible non-FVIII transgenic cassette for HA, encoding a fully functional single-chain FVIII-mimetic antibody.
Infusion of AAV8-Bi8 (1.2 × 1013 vector genome per kg) provides sustained FVIII-mimetic expression, and fully corrects bleeding in HA mice.
Abstract
The recent approval of adeno-associated virus (AAV)–based gene therapies for hemophilia A (HA) represents a major advancement in the management of this X-linked bleeding disorder, offering multiyear bleed protection and improved quality of life over factor VIII (FVIII) replacement. However, challenges remain, including concerns over long-term durability of expression and the difficulty of packaging the oversized FVIII transgene into AAV vectors. To address these limitations, we developed AAV8-Bi8, a liver-directed gene therapy encoding Bi8, a novel 54.5-kilodalton FVIII-mimetic antibody. Bi8 is expressed as a compact, single-chain tandem, single-chain fragment variable, and is delivered via a 4.4-kilobase expression cassette packaged within AAV8 capsids, well within the vector packaging capacity. In vitro, Bi8 demonstrated FVIII-mimetic activity, and effectively corrected FVIII-deficient human plasma to levels comparable with emicizumab, the current market standard. In vivo, a single administration of AAV8-Bi8 in FVIII-deficient mice resulted in dose-dependent, durable expression of Bi8, complete phenotypic correction of bleeding, and therapeutic equivalence to both emicizumab-treated and wild-type animals. Importantly, no toxicity or antidrug antibody responses were observed. This approach, based on delivering FVIII-mimetic antibodies through AAV rather than truncated FVIII transgenes, could provide a more flexible and efficient platform for gene therapy in HA. AAV8-Bi8 has the potential to offer sustained, lifelong hemostatic control, including in patients who have developed inhibitors to FVIII.
References
1.
Muczynski
V
, Christophe
OD
, Denis
CV
, Lenting
PJ
. Emerging therapeutic strategies in the treatment of hemophilia A
. Semin Thromb Hemost
. 2017
;43
(6
):581
-590
.2.
Srivastava
A
, Santagostino
E
, Dougall
A
, et al. WFH guidelines for the management of hemophilia, 3rd edition
. Haemophilia
. 2020
;26
(suppl 6
):1
-158
.3.
Peyvandi
F
, Mannucci
PM
, Garagiola
I
, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A
. N Engl J Med
. 2016
;374
(21
):2054
-2064
.4.
Gouw
SC
, van der Bom
JG
, Ljung
R
, et al. Factor VIII products and inhibitor development in severe hemophilia A
. N Engl J Med
. 2013
;368
(3
):231
-239
.5.
Eckhardt
CL
, Loomans
JI
, van Velzen
AS
, et al. Inhibitor development and mortality in non-severe hemophilia A
. J Thromb Haemost
. 2015
;13
(7
):1217
-1225
.6.
Oomen
I
, Camelo
RM
, Rezende
SM
, et al. Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis
. Res Pract Thromb Haemost
. 2023
;7
(1
):100020
.7.
Sampei
Z
, Igawa
T
, Soeda
T
, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity
. PLoS One
. 2013
;8
(2
):e57479
.8.
Lenting
PJ
, Denis
CV
, Christophe
OD
. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
. Blood
. 2017
;130
(23
):2463
-2468
.9.
Oldenburg
J
, Mahlangu
JN
, Kim
B
, et al. Emicizumab prophylaxis in hemophilia A with inhibitors
. N Engl J Med
. 2017
;377
(9
):809
-818
.10.
Mahlangu
J
, Oldenburg
J
, Paz-Priel
I
, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors
. N Engl J Med
. 2018
;379
(9
):811
-822
.11.
Reiss
UM
, Davidoff
AM
, Tuddenham
EGD
, et al. Sustained clinical benefit of AAV gene therapy in severe hemophilia B
. N Engl J Med
. 2025
;392
(22
):2226
-2234
.12.
Nathwani
AC
, Tuddenham
EG
, Rangarajan
S
, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B
. N Engl J Med
. 2011
;365
(25
):2357
-2365
.13.
Nathwani
AC
, Reiss
UM
, Tuddenham
EG
, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B
. N Engl J Med
. 2014
;371
(21
):1994
-2004
.14.
Symington
E
, Rangarajan
S
, Lester
W
, et al. Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A
. Haemophilia
. 2024
;30
(5
):1138
-1147
.15.
Ozelo
MC
, Mahlangu
J
, Pasi
KJ
, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A
. N Engl J Med
. 2022
;386
(11
):1013
-1025
.16.
Nathwani
AC
. Gene therapy for hemophilia
. Hematol Am Soc Hematol Educ Program
. 2022
;2022
(1
):569
-578
.17.
Mahlangu
J
, Kaczmarek
R
, von Drygalski
A
, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A
. N Engl J Med
. 2023
;388
(8
):694
-705
.18.
Herzog
RW
, Kaczmarek
R
, High
KA
. Gene therapy for hemophilia - from basic science to first approvals of “one-and-done” therapies
. Mol Ther
. 2025
;33
(5
):2015
-2034
.19.
Ward
NJ
, Buckley
SM
, Waddington
SN
, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression
. Blood
. 2011
;117
(3
):798
-807
.20.
McIntosh
J
, Lenting
PJ
, Rosales
C
, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
. Blood
. 2013
;121
(17
):3335
-3344
.21.
Bunting
S
, Zhang
L
, Xie
L
, et al. Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice
. Mol Ther
. 2018
;26
(2
):496
-509
.22.
Wu
Z
, Yang
H
, Colosi
P
. Effect of genome size on AAV vector packaging
. Mol Ther
. 2010
;18
(1
):80
-86
.23.
Samelson-Jones
BJ
, Small
JC
, George
LA
. Roctavian gene therapy for hemophilia A
. Blood Adv
. 2024
;8
(19
):5179
-5189
.24.
Dong
B
, Nakai
H
, Xiao
W
. Characterization of genome integrity for oversized recombinant AAV vector
. Mol Ther
. 2010
;18
(1
):87
-92
.25.
Greig
JA
, Wang
Q
, Reicherter
AL
, et al. Characterization of adeno-associated viral vector-mediated human factor VIII gene therapy in hemophilia A mice
. Hum Gene Ther
. 2017
;28
(5
):392
-402
.26.
Sefiane
T
, Maynadié
H
, Ettingshausen
CE
, et al. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc
. Haematologica
. 2024
;109
(6
):1836
-1848
.27.
Ferriere
S
, Peyron
I
, Christophe
OD
, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function
. Blood
. 2020
;136
(6
):740
-748
.28.
Kitazawa
T
, Esaki
K
, Tachibana
T
, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
. Thromb Haemost
. 2017
;117
(7
):1348
-1357
.29.
Sefiane
T
, McCluskey
G
, Clavel
M
, et al. Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice
. Haematologica
. 2025
;110
(9
):2064
-2075
.30.
Miao
CH
, Ohashi
K
, Patijn
GA
, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro
. Mol Ther
. 2000
;1
(6
):522
-532
.31.
Gray
SJ
, Foti
SB
, Schwartz
JW
, et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors
. Hum Gene Ther
. 2011
;22
(9
):1143
-1153
.32.
Retout
S
, Schmitt
C
, Petry
C
, Mercier
F
, Frey
N
. Population pharmacokinetic analysis and exploratory exposure-bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A
. Clin Pharmacokinet
. 2020
;59
(12
):1611
-1625
.33.
Hermans
C
, Pierce
GF
. Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
. Res Pract Thromb Haemost
. 2023
;7
(4
):100173
.34.
Mendell
JR
, Al-Zaidy
SA
, Lehman
KJ
, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy
. JAMA Neurol
. 2021
;78
(7
):834
-841
.35.
Gowda
V
, Atherton
M
, Murugan
A
, et al. Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom
. Lancet Reg Health Eur
. 2024
;37
:100817
.36.
Tan
YH
, Liu
M
, Nolting
B
, Go
JG
, Gervay-Hague
J
, Liu
GY
. A nanoengineering approach for investigation and regulation of protein immobilization
. ACS Nano
. 2008
;2
(11
):2374
-2384
.37.
Dickopf
S
, Georges
GJ
, Brinkmann
U
. Format and geometries matter: structure-based design defines the functionality of bispecific antibodies
. Comput Struct Biotechnol J
. 2020
;18
:1221
-1227
.38.
Hijazi
Y
, Klinger
M
, Kratzer
A
, et al. Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-Hodgkin lymphoma
. Curr Clin Pharmacol
. 2018
;13
(1
):55
-64
.39.
Ribera
JM
, Ferrer
A
, Ribera
J
, Genescà
E
. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
. Onco Targets Ther
. 2015
;8
:1567
-1574
.40.
Pyzik
M
, Kozicky
LK
, Gandhi
AK
, Blumberg
RS
. The therapeutic age of the neonatal Fc receptor
. Nat Rev Immunol
. 2023
;23
(7
):415
-432
.41.
Dennis
MS
, Zhang
M
, Meng
YG
, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins
. J Biol Chem
. 2002
;277
(38
):35035
-35043
.42.
Ullah
A
, Shin
G
, Lim
SI
. Human serum albumin binders: a piggyback ride for long-acting therapeutics
. Drug Discov Today
. 2023
;28
(10
):103738
.43.
Le Quellec
S
, Dane
A
, Enjolras
N
, et al. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins
. Haemophilia
. 2019
;25
(1
):e11
-e18
.44.
Hopp
J
, Hornig
N
, Zettlitz
KA
, et al. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein
. Protein Eng Des Sel
. 2010
;23
(11
):827
-834
.45.
Meetze
K
, Mehta
NK
, Li
B
, Michaelson
JS
, Baeuerle
PA
. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
. J Immunother Cancer
. 2023
;11
(8
):e007398
.46.
Schmitt
C
, Emrich
T
, Chebon
S
, et al. Low immunogenicity of emicizumab in persons with haemophilia A
. Haemophilia
. 2021
;27
(6
):984
-992
.47.
Zhu
M
, Wu
B
, Brandl
C
, et al. Blinatumomab, a bispecific T-cell engager (BiTE(®)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications
. Clin Pharmacokinet
. 2016
;55
(10
):1271
-1288
.48.
Long
BR
, Robinson
TM
, Day
JRS
, et al. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A
. Mol Ther
. 2024
;32
(7
):2052
-2063
.49.
Lund
J
, Jensen
K
, Burnier
L
, Ezban
M
. In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays
. J Thromb Haemost
. 2023
;21
(6
):1493
-1502
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal